Search
Zandatrigine
go.drugbank.com/drugs/DB19051InvestigationalZandatrigine is under investigation in clinical trial NCT05226780 (Extension Study to Evaluate How Safe and Tolerable NBI-921352 Is as an Adjunctive Therapy for Participants With SCN8A-DEE).
AZD2389
go.drugbank.com/drugs/DB22104InvestigationalAZD2389 is an investigational small molecule inhibitor of fibroblast activation protein (FAP).[L54978] It is currently undergoing safety, tolerability, and PK/PD profiling in clinical trials (e.g. … NCT06973005: A Study to Investigate How Multiple Oral Doses of AZD2389 Affect the Pharmacokinetics of Midazolam, Caffeine, and Bupropion in Healthy Participants).
AVI-5126
go.drugbank.com/drugs/DB05726InvestigationalAVI-526 is an improved formulation of [AVI-4557], developed for use on Vein Grafts before use in Heart by-Pass Graft Surgery. … The drug was under investigation in clinical trial NCT00451256 (Safety and Efficacy Study of AVI-5126 When Used on Vein Grafts Before Use in Heart by-Pass Graft Surgery (CABG)).
NGN-101
go.drugbank.com/drugs/DB18335InvestigationalNGN-101 is an adeno-associated virus serotype 9 vector with engineered transgene encoding the human CLN5 gene
ECT204
go.drugbank.com/drugs/DB18605InvestigationalECT204 is an autologous T-cell therapy whereby T cells are genetically modified to target tumor-specific antigens.
Prosetin
go.drugbank.com/drugs/DB18649InvestigationalProsetin is an orally administered blocker of MAP4K under investigation for the treatment of amyotrophic lateral sclerosis.[L48360]
Rovaleucel
go.drugbank.com/drugs/DB18691InvestigationalRovaleucel is an EBV-specific autologous T-cell therapy under investigation for the treatment of EBV-positive cancers.
Autologous DNP-conjugated tumour vaccine
go.drugbank.com/drugs/DB17361InvestigationalAutologous DNP-conjugated tumour vaccine, or melanoma vaccine, is an investigational autologous cell vaccine technology for melanoma.[A254806]
Trotabresib
go.drugbank.com/drugs/DB17421InvestigationalTrotabresib is an oral, potent, and reversible inhibitor of the epigenetic target bromodomain and extra-terminal (BET) proteins.
OPC1
go.drugbank.com/drugs/DB17944ExperimentalOPC1 is an oligodendrocyte progenitor cell therapy being investigated for the treatment of acute spinal cord injury.[L47082]